Here are 1-3 brief analogies for Zymeworks (ZYME):

• Like a clinical-stage Genentech, focused on developing advanced biologic drugs for cancer.
• An early-stage Regeneron Pharmaceuticals, specializing in innovative antibody therapies for cancer.

• zanidatamab: A novel bispecific antibody in clinical trials for treating biliary tract, gastroesophageal adenocarcinomas, and breast cancer.
• ZW49: A biparatopic anti-HER2 antibody-drug conjugate in clinical trials for treating advanced or metastatic HER2-expressing tumors.

Zymeworks (ZYME) is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes biotherapeutics. Given its stage and business model, Zymeworks primarily sells to other companies through strategic partnerships and licensing agreements rather than directly to individuals. Its major customers are the large pharmaceutical and biotechnology companies with which it collaborates or licenses its product candidates and technology platforms.

The major customer companies for Zymeworks include:

• Merck Sharp & Dohme Research Ltd. (part of Merck & Co., Inc., Symbol: MRK)
• Eli Lilly and Company (Symbol: LLY)
• Bristol-Myers Squibb company (Symbol: BMY)
• GlaxoSmithKline Intellectual Property Development Ltd. (part of GSK plc, Symbol: GSK)
• Daiichi Sankyo Co., Ltd. (Symbol: DSNKY - OTC; Primary listing on Tokyo Stock Exchange: 4568)
• Janssen Biotech, Inc. (part of Johnson & Johnson, Symbol: JNJ)
• BeiGene, Ltd. (Symbol: BGNE)
• LEO Pharma A/S (Private Company)
• Iconic Therapeutics, Inc. (Private Company)

Kenneth Galbraith, Chair and Chief Executive Officer

Mr. Galbraith has served as Zymeworks' Chief Executive Officer and Chair of its board of directors since January 2022. He brings over 35 years of experience as an executive, director, investor, and advisor in the biotechnology, medical device, pharmaceutical, and healthcare sectors. Prior to joining Zymeworks, he served as Executive in Residence at Syncona Investment Management Limited from April 2021 until January 2022. Mr. Galbraith founded Five Corners Capital Inc. in 2013 to manage the Ventures West Investment Funds. He also held CEO positions at Liminal BioSciences Inc. (from 2019 to 2020) and Fairhaven Pharmaceuticals Inc. (from 2017 to 2019). Earlier in his career, he was Chief Financial Officer at QLT, Canada's first biotechnology company, from 1987 to 2000, where he was instrumental in its growth and in achieving market approvals for several new medicines. He played a pivotal role in the $584 million buyout of AnorMED by Genzyme and has been involved with companies such as Alder Pharmaceuticals (sold to Lundbeck), Celator Pharmaceuticals (sold to Jazz Pharma), and Novadaq (sold to Stryker). His extensive background includes roles with venture capital firms like Ventures West Capital and Syncona Investment Management Limited, indicating a pattern of managing companies backed by investment firms.

Leone Patterson, Executive Vice President, Chief Business Officer and Chief Financial Officer

Ms. Patterson was appointed Executive Vice President, Chief Business Officer, and Chief Financial Officer, effective September 1, 2024, and assumed the duties of the principal financial officer. She brings more than 20 years of experience in public company biotechnology. Before Zymeworks, Ms. Patterson served as Chief Financial and Business Officer at Tenaya Therapeutics since June 2021. She previously held several leadership roles at Adverum Biotechnologies, including Chief Financial Officer, President, Chief Executive Officer, and Director. Her career also includes senior finance positions at Diadexus, Transcept, Exelixis, Novartis, and Chiron, and she began her career in the audit practice of KPMG. Ms. Patterson has served as CEO and President of Adverum Biotechnologies.

Dr. Paul Moore, Chief Scientific Officer

Dr. Moore joined Zymeworks in July 2022 and serves as Chief Scientific Officer. He has over 25 years of experience in biologics drug discovery and development in biotechnology research, contributing to the discovery and development of FDA-approved and clinical-stage biologics for cancer and autoimmune conditions. Prior to Zymeworks, he was Vice President, Cell Biology, and Immunology at MacroGenics from April 2008 to July 2022. Before MacroGenics, Dr. Moore was Director of Cell Biology at Celera and Director of Lead Product Development at Human Genome Sciences (HGS), where he managed programs that led to the discovery, development, approval, and commercialization of Benlysta. HGS was acquired by GlaxoSmithKline for $3.6 billion in 2012.

Mark Hollywood, Executive Vice President and Chief Operating Officer

Mr. Hollywood was promoted to Executive Vice President and Chief Operating Officer in January 2026, expanding his responsibilities in Technology and Manufacturing Operations, Quality, and Alliance/Program Management. He joined Zymeworks as Senior Vice President, Technical and Manufacturing Operations in April 2019. He brings 25 years of experience in the biopharmaceutical industry, having previously served as Vice President and Head of ZymoGenetics, Inc. (a Bristol-Myers Squibb company), where he oversaw biologics portfolio deliverables, including technical and manufacturing operations.

Dr. Sabeen Mekan, Senior Vice President and Chief Medical Officer

Dr. Mekan was appointed Senior Vice President and Chief Medical Officer, effective February 1, 2026. Before joining Zymeworks, she was Executive Director, Global Development Lead for the lung and gastrointestinal cancer franchises at Gilead Sciences. Prior to Gilead, Dr. Mekan served as Senior Medical Director, Oncology R&D at Daiichi Sankyo U.S., where she was responsible for the global clinical development of two antibody-drug conjugates. She began her pharmaceutical career as a Medical Director focusing on immune-oncology at Bristol-Myers Squibb.

The key risks to Zymeworks' business include clinical trial failures and regulatory hurdles, intense market competition, and the inherent volatility of its milestone-driven revenue model and reliance on partnerships.

1. Clinical Trial Failure and Regulatory Approval: As a clinical-stage biopharmaceutical company, Zymeworks' long-term growth and financial viability are heavily dependent on the successful progression of its product candidates through preclinical and clinical development, and ultimately, obtaining regulatory approvals. There is a historically high failure rate in biopharmaceutical development, meaning promising early data may not translate into later-stage success due to safety, efficacy, clinical execution challenges, or evolving regulatory expectations. This risk is exemplified by the company's decision in September 2025 to discontinue the clinical development of ZW171, a T-cell engager, after assessing its benefit-risk profile in a Phase 1 study. Even with strong balance sheet metrics, regulatory hurdles and clinical trial outcomes remain significant sector-specific risks.
2. Intense Market Competition: Zymeworks operates within a highly competitive biopharmaceutical industry where numerous companies are developing alternative therapies targeting similar indications. Its lead product candidates, such as zanidatamab, face competition from established therapies and other drugs in development, which could impact Zymeworks' potential market share and pricing. Sustained success in this environment requires continuous innovation and effective commercialization strategies to differentiate its products.
3. Dependence on Partnerships and Volatility of Milestone-Driven Revenue: Zymeworks' financial health and revenue generation are significantly dependent on the achievement of clinical and regulatory milestones from its strategic partnerships. While these collaborations provide crucial financial support and leverage external expertise for drug development and commercialization, they also expose the company to financial risk if clinical trials are delayed, fail to meet regulatory requirements, or if partners' strategic priorities shift. The company's revenue stream has been characterized by volatility due to its milestone-driven nature, which contrasts with more predictable recurring product sales for commercial-stage companies.

For Zymeworks (symbol: ZYME), the addressable markets for its main product candidates are as follows:

Zanidatamab

• Biliary Tract Cancer (BTC): The total market size for biliary tract cancer in the 7MM (United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan) was approximately USD 1,160 million in 2024 and is projected to increase during the forecast period (2025–2034). Zymeworks targets a subset of this market (second-line HER2+ BTC), indicating a smaller opportunity within this overall market. Separately, another source suggests the BTC market represents a small market opportunity, less than $100 million per annum. Approximately 12,000 people are diagnosed with HER2-positive BTC each year across the U.S., Europe, and Japan.
• Gastroesophageal Adenocarcinomas (GEA): The market opportunity for HER2-positive gastroesophageal adenocarcinoma (GEA) is likely a $2 billion market opportunity, with the global market for gastroesophageal adenocarcinoma expected to surpass $3 billion. Jazz Pharmaceuticals, Zymeworks' partner, believes zanidatamab has a "$2 billion-plus peak potential" across multiple indications, including GEA. Globally, approximately 20% of GEA patients have HER2+ disease. The broader global market for stomach cancer treatments is valued at $5.37 billion in 2024 and could potentially double by 2030.
• Breast Cancer: The global HER2-positive breast cancer treatment market size is estimated at USD 11.38 billion in 2026 and is projected to reach USD 13.79 billion by 2031. However, Zymeworks currently targets a smaller population within this market, specifically a post-T-DXd population in the midterm. HER2-positive breast cancer accounts for 15–20% of all breast cancer cases.

ZW49

Zymeworks formally discontinued the clinical development program for ZW49 (also known as zanidatamab zovodotin) following a strategic review in the second quarter of 2024. Therefore, there is no addressable market for this product.

Zymeworks Inc. (ZYME) anticipates several key drivers for future revenue growth over the next two to three years, primarily stemming from the continued development and commercialization of its lead product candidate, zanidatamab, as well as ongoing and new strategic collaborations and the progression of its pipeline.

Here are the expected drivers of future revenue growth:

1. Commercialization and Royalty Revenue from Zanidatamab in Biliary Tract Cancer (BTC): Zanidatamab (marketed as Ziihera) has received accelerated approval by the FDA for the treatment of previously treated, unresectable or metastatic HER2-positive biliary tract cancer. Further approvals include Canada and the UK, with conditional marketing authorization in Europe in July 2025, which is expected to increase future royalties. A conditional approval of the Biologics License Application (BLA) for zanidatamab in second-line HER2-positive BTC by the NMPA in China in Q2 2025 resulted in a $20.0 million milestone payment. These approvals and commercialization efforts by Zymeworks' partners, such as Jazz Pharmaceuticals and BeiGene, are expected to generate increasing royalty revenues.
2. Potential Commercial Launch and Milestone Payments for Zanidatamab in Gastroesophageal Adenocarcinoma (GEA): Zymeworks' partner, Jazz Pharmaceuticals, plans to submit a supplemental BLA in the first half of 2026 for zanidatamab in the U.S. as a first-line treatment for HER2-positive locally advanced or metastatic GEA, with a potential commercial launch anticipated in the second half of 2026. The company is eligible to receive substantial milestone payments totaling up to $440.0 million related to anticipated regulatory approvals of Ziihera in GEA across the U.S. ($250.0 million), EU ($100.0 million), Japan ($75.0 million), and China ($15.0 million).
3. Milestone Payments and Royalties from Existing and New Strategic Collaborations: Zymeworks maintains active licensing arrangements with several major pharmaceutical and biotechnology partners. The company has historically generated revenue through significant clinical and regulatory milestones and the exercise of options under these collaborations, including those with J&J, Boehringer Ingelheim, GSK, Daiichi Sankyo, and BMS. Zymeworks is eligible to earn additional milestone payments as partnered products advance in development, and its strategy includes partnering assets at key development milestones to generate upfront payments and long-term royalties.
4. Advancement of Wholly-Owned Early-Stage Pipeline Candidates: Zymeworks is focused on progressing its wholly-owned pipeline, including candidates such as ZW191, ZW251, and ZW209. ZW191, a folate receptor alpha ADC, has shown promising early clinical data. The company plans an Investigational New Drug (IND) filing for ZW209, a DLL3-directed trispecific T-cell engager, in the first half of 2026, and initiated a Phase 1 study for ZW251 in 2025. Successful progression of these and other early-stage candidates could lead to future licensing agreements, partnership deals, or eventual commercialization, contributing to revenue growth within the forecast period.

Share Repurchases

• Zymeworks authorized a new $125.0 million share repurchase program in November 2025.
• As of March 2, 2026, $62.5 million had been utilized under the $125.0 million share repurchase program.
• In August 2024, the company authorized a Share Repurchase Program of up to $60.0 million, with an initial $30.0 million in repurchases planned for the second half of 2024 and the remaining $30.0 million reserved for future repurchases.

Share Issuance

• In January 2022, Zymeworks completed an underwritten public offering of common shares and pre-funded warrants, generating approximately $115.0 million in gross proceeds.

Inbound Investments

• Zymeworks secured a $250 million non-recourse royalty-backed note financing from Royalty Pharma in March 2026, with repayment tied to 30% of worldwide tiered royalties on Ziihera.
• The company received a $25.0 million development milestone payment from Johnson & Johnson in the third quarter of 2025.
• In February 2025, Zymeworks achieved a $14 million cash research milestone from its collaboration with GSK.

Capital Expenditures

• Capital expenditures totaled -$0.58 million in the most recent quarter (Q4 2025) and -$1.52 million for the last 12 months ending Q4 2025.
• Zymeworks anticipated capital expenditures of approximately $15 million for the calendar year 2023.
• The company's strategy of leveraging partnerships for late-stage clinical trials and commercialization aims to significantly reduce its own capital expenditure.